Related Experiment Video
Updated: Aug 27, 2026

Screening for Functional Non-coding Genetic Variants Using Electrophoretic Mobility Shift Assay (EMSA) and DNA-affinity Precipitation Assay (DAPA)
Published on: August 21, 2016
Feasibility and outcomes of the DNA Screen nationwide adult genomic screening pilot
Paul Lacaze1, Jane Tiller1, Adam Brotchie1
1School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia.
Abstract:
Population genomic screening enables the identification of individuals at high risk of medically actionable conditions before disease onset, yet real-world feasibility studies are lacking. Informed by prior cost-effectiveness modelling, we conducted a prospective nationwide pilot targeting young adults in Australia (aged 18 to 40 years), offering genomic screening for 10 genes linked to hereditary breast and ovarian cancer, Lynch syndrome, and familial hypercholesterolemia. Of 30,017 registrants, 18,573 were invited and 10,263 completed genomic screening (median age 31.9 years; 45.5% men; 30.0% culturally or linguistically diverse). We detected pathogenic/likely pathogenic variants in 202 (2.0%). Of the 189 referred for clinical follow-up, 97.9% accepted and 87.3% attended appointments. Notably, 74.5% of attendees were ineligible for government-funded criteria-based genomic testing. Our findings demonstrate the feasibility of adult population genomic screening, including high public engagement, clinical uptake, and identification of individuals ineligible for current criteria, supporting the further development of adult population genomic screening in Australia.

